- |||||||||| voxalatamab (JNJ-63898081) / J&J
P1 data, Clinical Trial,Phase I, Journal, IO biomarker, Metastases: Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. (Pubmed Central) - May 29, 2023 CRS and IRR could be partially mitigated by SC dosing, step-up priming, and a combination of both strategies. T cell redirection for prostate cancer is feasible and PSMA is a potential therapeutic target for T cell redirection in prostate cancer.
- |||||||||| voxalatamab (JNJ-63898081) / J&J
Trial completion, Trial completion date, Metastases: A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov) - Dec 3, 2021 P1, N=40, Completed, ADA resulting in decreased exposure occurred in the majority of pts treated SC. Active, not recruiting --> Completed | Trial completion date: Nov 2022 --> Sep 2021
- |||||||||| voxalatamab (JNJ-63898081) / J&J
Enrollment closed, Enrollment change, Metastases: A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors (clinicaltrials.gov) - Jul 21, 2021 P1, N=40, Active, not recruiting, Active, not recruiting --> Completed | Trial completion date: Nov 2022 --> Sep 2021 Recruiting --> Active, not recruiting | N=90 --> 40
|